Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 1
1984 2
1985 2
1986 4
1987 3
1988 3
1989 5
1990 3
1991 4
1992 14
1993 18
1994 3
1995 3
1996 12
1997 5
1998 8
1999 12
2000 9
2001 7
2002 11
2003 11
2004 12
2005 16
2006 21
2007 19
2008 20
2009 24
2010 30
2011 32
2012 26
2013 38
2014 20
2015 30
2016 29
2017 26
2018 34
2019 38
2020 23
2021 37
2022 31
2023 40
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

618 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.
Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, Lass-Flörl C, Lewis RE, Munoz P, Verweij PE, Warris A, Ader F, Akova M, Arendrup MC, Barnes RA, Beigelman-Aubry C, Blot S, Bouza E, Brüggemann RJM, Buchheidt D, Cadranel J, Castagnola E, Chakrabarti A, Cuenca-Estrella M, Dimopoulos G, Fortun J, Gangneux JP, Garbino J, Heinz WJ, Herbrecht R, Heussel CP, Kibbler CC, Klimko N, Kullberg BJ, Lange C, Lehrnbecher T, Löffler J, Lortholary O, Maertens J, Marchetti O, Meis JF, Pagano L, Ribaud P, Richardson M, Roilides E, Ruhnke M, Sanguinetti M, Sheppard DC, Sinkó J, Skiada A, Vehreschild MJGT, Viscoli C, Cornely OA. Ullmann AJ, et al. Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38. doi: 10.1016/j.cmi.2018.01.002. Epub 2018 Mar 12. Clin Microbiol Infect. 2018. PMID: 29544767 Free article.
Combinations of antifungals as primary treatment options are not recommended. Therapeutic drug monitoring is strongly recommended for patients receiving posaconazole suspension or any form of voriconazole for IA treatment, and in refractory disease, where a personalized ap …
Combinations of antifungals as primary treatment options are not recommended. Therapeutic drug monitoring is strongly recommended for …
New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A, Bravo GM. Bazinet A, et al. Curr Treat Options Oncol. 2022 May;23(5):668-687. doi: 10.1007/s11864-022-00965-1. Epub 2022 Mar 23. Curr Treat Options Oncol. 2022. PMID: 35320468 Review.
Some LR-MDS patient subgroups may also benefit from specific therapies including luspatercept (MDS with ring sideroblasts), lenalidomide (MDS with deletion 5q), or immunosuppressive therapy (hypocellular MDS). ...In higher-risk MDS (HR-MDS), therapy seeks to …
Some LR-MDS patient subgroups may also benefit from specific therapies including luspatercept (MDS with ring sideroblasts), lenalidom …
MYC as a target for cancer treatment.
Duffy MJ, O'Grady S, Tang M, Crown J. Duffy MJ, et al. Cancer Treat Rev. 2021 Mar;94:102154. doi: 10.1016/j.ctrv.2021.102154. Epub 2021 Jan 19. Cancer Treat Rev. 2021. PMID: 33524794 Free article. Review.
Although no compound directly targeting MYC has yet progressed to clinical testing, APTO-253, which partly acts by decreasing expression of MYC, is currently undergoing a phase I clinical trial in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic …
Although no compound directly targeting MYC has yet progressed to clinical testing, APTO-253, which partly acts by decreasing expression of …
Anemia at older age: etiologies, clinical implications, and management.
Stauder R, Valent P, Theurl I. Stauder R, et al. Blood. 2018 Feb 1;131(5):505-514. doi: 10.1182/blood-2017-07-746446. Epub 2017 Nov 15. Blood. 2018. PMID: 29141943 Free article. Review.
Anemia is quite frequently diagnosed in older individuals and is a key indicator of various reactive and clonal conditions. Many underlying diseases, like myelodysplastic syndrome (MDS), develop preferentially in elderly individuals. ...
Anemia is quite frequently diagnosed in older individuals and is a key indicator of various reactive and clonal conditions. Many underlying …
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Kantarjian HM, Kadia TM, DiNardo CD, Welch MA, Ravandi F. Kantarjian HM, et al. Cancer. 2021 Apr 15;127(8):1186-1207. doi: 10.1002/cncr.33477. Epub 2021 Mar 18. Cancer. 2021. PMID: 33734442 Free article. Review.
We also consider within each subset whether the AML is primary or secondary (therapy-related, evolving from untreated or treated myelodysplastic syndrome or myeloproliferative neoplasm). ...Adding venetoclax, FLT3, and IDH inhibitors into these regimens has r …
We also consider within each subset whether the AML is primary or secondary (therapy-related, evolving from untreated or treated m …
VEXAS syndrome: Clinical manifestations, diagnosis, and treatment.
Loeza-Uribe MP, Hinojosa-Azaola A, Sánchez-Hernández BE, Crispín JC, Apodaca-Chávez E, Ferrada MA, Martín-Nares E. Loeza-Uribe MP, et al. Reumatol Clin (Engl Ed). 2024 Jan;20(1):47-56. doi: 10.1016/j.reumae.2023.12.004. Epub 2023 Dec 29. Reumatol Clin (Engl Ed). 2024. PMID: 38160120 Free article. Review.
VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is an adult-onset autoinflammatory syndrome characterized by somatic mutations in the UBA1 gene and is considered the prototype of hematoinflammatory diseases. Patients with VEXAS syndrome …
VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is an adult-onset autoinflammatory syndrome characte …
European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia.
Maertens JA, Girmenia C, Brüggemann RJ, Duarte RF, Kibbler CC, Ljungman P, Racil Z, Ribaud P, Slavin MA, Cornely OA, Peter Donnelly J, Cordonnier C; European Conference on Infections in Leukaemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and; European Conference on Infections in Leukaemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN). Maertens JA, et al. J Antimicrob Chemother. 2018 Dec 1;73(12):3221-3230. doi: 10.1093/jac/dky286. J Antimicrob Chemother. 2018. PMID: 30085172 Review.
For patients undergoing remission-induction chemotherapy for AML and myelodysplastic syndrome (MDS), fluconazole can still offer an alternative provided it forms part of an integrated care strategy that includes screening with biomarkers and imaging. ...Posac …
For patients undergoing remission-induction chemotherapy for AML and myelodysplastic syndrome (MDS), fluconazole can still off …
Ineffective erythropoiesis and its treatment.
Cazzola M. Cazzola M. Blood. 2022 Apr 21;139(16):2460-2470. doi: 10.1182/blood.2021011045. Blood. 2022. PMID: 34932791 Free article.
This mechanism is primarily responsible for anemia in inherited disorders like beta-thalassemia, inherited sideroblastic anemias, and congenital dyserythropoietic anemias, as well as in acquired conditions like some subtypes of myelodysplastic syndrome (MDS). The in …
This mechanism is primarily responsible for anemia in inherited disorders like beta-thalassemia, inherited sideroblastic anemias, and congen …
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Stahl M, Bewersdorf JP, Xie Z, Porta MGD, Komrokji R, Xu ML, Abdel-Wahab O, Taylor J, Steensma DP, Starczynowski DT, Sekeres MA, Sanz G, Sallman DA, Roboz GJ, Platzbecker U, Patnaik MM, Padron E, Odenike O, Nimer SD, Nazha A, Majeti R, Loghavi S, Little RF, List AF, Kim TK, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Gore SD, Greenberg P, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Daver NG, Churpek JE, Carraway HE, Buckstein R, Brunner AM, Boultwood J, Borate U, Bejar R, Bennett JM, Wei AH, Santini V, Savona MR, Zeidan AM. Stahl M, et al. Blood Rev. 2023 Nov;62:101128. doi: 10.1016/j.blre.2023.101128. Epub 2023 Aug 19. Blood Rev. 2023. PMID: 37704469 Review.
The guidelines for classification, prognostication, and response assessment of myelodysplastic syndromes/neoplasms (MDS) have all recently been updated. ...We also address the importance of patient centered care by discussing the value of quality-of-life assessment. …
The guidelines for classification, prognostication, and response assessment of myelodysplastic syndromes/neoplasms (MDS) have all rec …
Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment.
Georges GE, Doney K, Storb R. Georges GE, et al. Blood Adv. 2018 Aug 14;2(15):2020-2028. doi: 10.1182/bloodadvances.2018021162. Blood Adv. 2018. PMID: 30108110 Free PMC article. Review.
This review will summarize the key areas of progress in the use of allogeneic hematopoietic cell transplantation and nontransplant immunosuppressive therapy (IST) for the treatment of aplastic anemia and then summarize the recommendations for first-line treatment. ...We ma …
This review will summarize the key areas of progress in the use of allogeneic hematopoietic cell transplantation and nontransplant immunosup …
618 results